Landmark Bio
Landmark Bio is seeking a Director of Business Development for the Eastern U.S. to expand strategic relationships within the Cell and Gene Therapy space. The role involves driving revenue growth through securing new business, developing client relationships, and representing technical capabilities in viral vectors, mRNA, and cell & gene therapies.
Landmark Bio is a cell and gene therapy manufacturing company that develops innovative technologies, products, and services to bridge the gap from bench to patient. They provide end-to-end support—process development, scale-up and GMP manufacturing, analytical testing, and regulatory-ready workflows—to translate research into clinical‑grade therapies. Focused on enabling academic groups and biotech partners, Landmark Bio offers scalable, compliant solutions and partnership models to accelerate commercialization and bring therapies to patients.
Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology
Jan 6, 2026
Artis expands its territory with acquisition of Landmark Bio for cell and gene manufacturing
Apr 2, 2025
Artis BioSolutions Emerges from Stealth, Acquires Landmark Bio
Apr 3, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Landmark Bio.
New genetic medicine CDMO acquires Landmark Bio
Apr 2, 2025
Cell Therapy Scientist
AstraZeneca
Sr/Principal Scientist - Upstream Process Development
Genezen
Bench Scientist
Global Channel Management
Senior Scientist Vector Engineering
AstraZeneca
Director of Vector Engineering and Manufacturing Quality - Cell Therapy
Marriott International
EMEA Associate Director, Business Development
Lonza